Please assess the completion status of the following clinical trial:

Trial Title: Behavioral Activation and Varenicline for Smoking Cessation in Depressed Smokers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~1. adult (18 years of age or older) daily cigarette smokers (1+ cigarettes per day)~2. meet criteria for current or lifetime MDD without psychotic features~3. have or are willing to acquire a personal email address and access to a camera phone or other method for submission of therapy practice assignments~4. speak, read, and write fluently in English~5. able to provide written informed consent~6. intend to reside in the geographic area for \>8 months~7. women of childbearing potential must agree to use a medically acceptable method of birth control or abstain from sexual intercourse during the time they are taking study medication and for at least one month after the medication period ends.~8. The candidate had to answer yes to the question: Are you interested in quitting smoking?~Exclusion criteria:~1. current enrollment or plan to enroll in another smoking cessation program in the next 8 months~2. regular (daily) use of e-cigarettes, chewing tobacco, snuff, snus, or other tobacco products~3. current use or plan to use nicotine replacement therapy or other smoking cessation medication within the next 8 months~4. medications indicated for bipolar or psychotic disorder if prescribed for bipolar or psychotic disorder~5. pregnant or planning to become pregnant within the next 8 months, or breast feeding~6. history of seizures or current seizure disorder without medication~7. history of severe (stage IV or V) chronic kidney disease including current or prior end stage renal disease on either hemodialysis or peritoneal dialysis or prior renal transplant~8. any prior solid organ transplant or prior hematopoietic stem cell transplant~9. alcohol consumption exceeding 28 drinks per week~10. cirrhosis or end-stage liver disease~11. systolic blood pressure \>185 mmHg or diastolic blood pressure \>110 mmHg after two readings or symptomatic uncontrolled stage II hypertension~12. unstable cardiovascular disease within 3 months prior to baseline or other cardiovascular disease requiring hospitalization~13. prior hospitalization for heart failure~14. previous allergic reaction to varenicline~15. high suicide risk based on the Columbia Suicide Severity Rating Scale~16. lifetime bipolar or psychotic disorder as determined by either self-report or clinical interview

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard treatment + placebo varenicline (Type: PLACEBO_COMPARATOR): Standard behavioral smoking cessation treatment plus placebo varenicline
- BASC + placebo varenicline (Type: EXPERIMENTAL): Behavioral activation for smoking cessation plus placebo varenicline
- Standard treatment + active varenicline (Type: ACTIVE_COMPARATOR): Standard behavioral smoking cessation treatment plus active varenicline
- BASC + active varenicline (Type: EXPERIMENTAL): Behavioral activation for smoking cessation plus active varenicline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete